CAMBRIDGE, Mass., April 17 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 - 21, 2010, in Washington, D.C.
Poster 1806 shows pre-clinical data on MM-121’s efficacy as a single agent, and in combination with tamoxifen and paclitaxel, in ER+ and triple negative breast cancer studies.
MM-121
Poster 3756 shows pre-clinical data on efforts to derive a predictive biomarker signature that identifies tumors responsive to MM-121.
MM-111
MM-111 is a bispecific antibody designed to specifically inhibit ErbB3 signaling in ErbB2- overexpressing cancer cells. MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it from activating pAKT, an important mediator of cancer cell survival.
Title: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit
Poster Session: Experimental and Molecular Therapeutics 22
Number: 3485
Date/Time: Tuesday April 20, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 21 Permanent Abstract
CONTACT: Kathleen Petrozzelli, Corporate Communications, Merrimack,
+1-617-441-1043, or Betsy Stevenson, RaymondStevenson Healthcare
Communications, +1-860-984-1424
Web site: http://www.merrimackpharma.com/
